Composition priority for mucosal and oral administration containing HCG fragments This application was filed with EP03076028.4 filed with the European Patent Office (EPO) on April 8, 2003 and with EPO on April 8, 2003 EP03076029.2, EP03076027.6 filed with EPO on April 8, 2003, EP03076026.8 filed with EPO on April 8, 2003, EP03076022.7 filed with EPO on April 8, 2003, US10 / 409,671, EP03076021.9 filed with EPO on April 8, 2003, EP0307625.0 filed with EPO on April 8, 2003, EP03076024.3 filed with EPO on April 8, 2003, EP 03076030.0, 200, filed with EPO on April 8, 2003 April 8 days EP03076023.5 filed to the EPO, the claims CN03131227.6 priority of which was filed on China Patent Office on April 30, 2003.

摘要

The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantationrelated disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, said pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.